A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
about
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside ReviewOptions for empagliflozin in combination therapy in type 2 diabetes mellitusDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEmpagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Fasting plasma glucose and serum uric acid levels in a general Chinese population with normal glucose tolerance: A U-shaped curve.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesSGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuriaEmpagliflozin in the treatment of type 2 diabetes: evidence to dateThe sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicityExposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trialIpragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trialsEfficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.The role of empagliflozin in the management of type 2 diabetes by patient profile.Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes.The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes.Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialEfficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialLong-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapySodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes MellitusSGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus.SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.Empagliflozin for the treatment of Type 2 diabetes.Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation.Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.
P2860
Q24563917-457D3C18-062E-42A8-AD61-074B8682B083Q26745771-0B3C69A1-C921-48F9-A030-45932AB5B331Q26749281-2608685F-BFDA-486D-9853-C9E315D710C3Q28072765-DDF5D768-B2B5-4B4F-9B1C-33558C869350Q28079134-C4E1A606-6EB3-429A-BA32-3A71DFC96C50Q28553482-E3DCC1FC-FE3D-456D-BCE8-B604D7DEFA46Q33837017-A66951C5-3A53-44FF-872C-ADD8763CE83AQ33848499-D4A52F21-0FDD-4FED-961D-369DAEFC6FBCQ33890770-3214E1D1-D113-4B9F-890F-99762038DD0EQ34198692-A84DDF26-C512-4A51-BB91-CA1BA82E4897Q34470786-FC0C9F25-88F7-4329-AA98-DAE773C2524BQ34502358-852C07C9-E8A7-417F-8953-590E4409D3A7Q34524690-2B41F1A1-8A2E-4335-9B26-D860EFC8E002Q34635575-BD73C1CE-7AF3-417E-8E7A-AA50651F2744Q34804900-C1667809-E42F-4762-887C-B71509BD605FQ35049845-66DB3781-9304-4090-83FC-D863EDACFA0CQ35068181-E4E0180C-4DAF-497E-8F79-CBF6C6B1B2EDQ35157497-2D9C0F55-ACA1-483A-A17D-4AFAE11B3413Q35592873-7A973419-E898-4FEF-B52E-201486566E97Q35831426-1FBCC5FA-AE5B-4E5D-BE97-D400F2388B49Q35906490-73F3E2FE-B37C-4A84-B660-0ABEAC379E32Q36354599-F7649326-4814-475F-96F4-FEADE352D887Q36828139-4A3E37C7-AF9E-4BD6-A221-0276BD233AE5Q37239278-9D9D1361-E6BE-4A0D-828B-19F364E100B9Q37278239-C0CBC7FF-6D99-426F-97B7-E6E38D1C9A0EQ37302078-F098707E-C702-4E1E-B1E2-94A1BC6C952BQ37331262-337C7310-5E3D-489D-9235-067C419C5A70Q37351709-5508DA18-CC7F-4A7F-9A97-373C227E7E3AQ37461695-D3CCA26F-CFB3-4561-AD1B-ED9878932DB1Q37468412-52E60610-993E-40FC-A5D3-6D3E5ECD5906Q37575455-E4C0C9A9-31DA-48CF-80C2-C1BA7FCD813BQ38126109-8C15AC25-0DD3-4A12-B3D6-B14BCF7C7014Q38130748-1A9A3604-3D2A-45FB-B836-146BA156260AQ38151450-082BCDBD-E3E4-4E19-ADC4-B8501C3AE6B9Q38176145-67E9A496-B68D-4955-8462-175C5C2D7C1AQ38203327-625D3E9C-BDF1-4C5F-BB1C-0DC2963037B1Q38205581-184881E6-D05E-43E0-957C-EE6273DBD469Q38215995-C2B54790-6C57-42EF-8F3A-80BAC60A95BCQ38219490-A7F8E640-45B0-4739-8E03-C30D971CBEE8Q38255999-322EBA8E-F5AE-4449-88F7-56EBA9177C0B
P2860
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A Phase IIb, randomized, place ...... patients with type 2 diabetes.
@en
A Phase IIb, randomized, place ...... patients with type 2 diabetes.
@nl
type
label
A Phase IIb, randomized, place ...... patients with type 2 diabetes.
@en
A Phase IIb, randomized, place ...... patients with type 2 diabetes.
@nl
prefLabel
A Phase IIb, randomized, place ...... patients with type 2 diabetes.
@en
A Phase IIb, randomized, place ...... patients with type 2 diabetes.
@nl
P2093
P2860
P921
P356
P1476
A Phase IIb, randomized, place ...... patients with type 2 diabetes.
@en
P2093
E Ferrannini
E Seewaldt-Becker
H J Woerle
S Pinnetti
P2860
P304
P356
10.1111/DOM.12081
P577
2013-03-04T00:00:00Z